10-Q Filing

ALIGNMENT HEALTHCARE, INC. CIK: 1832466 Q1 2023

Filing Information

Form Type	10-Q
Accession Number	`0000950170-23-017873`
Period End Date	20230331
Filing Date	20230504
Fiscal Year	2023
Fiscal Period	Q1
XBRL Instance	alhc-20230331_htm.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 75 Income Statement 38 Cash Flow Statement 73 Stockholders Equity 22

Balance Sheet 75 line items

Line Item	Tag	Value	Unit	Period
Allowance for credit losses	`AllowanceForDoubtfulAccountsReceivableCurrent`	-	USD	Point-in-time
Allowance for credit losses	`AllowanceForDoubtfulAccountsReceivableCurrent`	$1.00K	USD	Point-in-time
Preferred stock, par value	`PreferredStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Preferred stock, par value	`PreferredStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$448.83M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$409.55M	USD	Point-in-time
Preferred stock, shares authorized	`PreferredStockSharesAuthorized`	100.00M	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$384.26M	USD	Point-in-time
Preferred stock, shares authorized	`PreferredStockSharesAuthorized`	100.00M	shares	Point-in-time
Accounts receivable (less allowance for credit losses of $1 at March 31, 2023 and $0 at December 31, 2022, respectively)	`AccountsReceivableNetCurrent`	$92.89M	USD	Point-in-time
Accounts receivable (less allowance for credit losses of $1 at March 31, 2023 and $0 at December 31, 2022, respectively)	`AccountsReceivableNetCurrent`	$125.28M	USD	Point-in-time
Preferred stock, shares issued	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Preferred stock, shares issued	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Preferred stock, shares outstanding	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Short-term investments	`ShortTermInvestments`	-	USD	Point-in-time
Short-term investments	`ShortTermInvestments`	$103.48M	USD	Point-in-time
Preferred stock, shares outstanding	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Common stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$57.89M	USD	Point-in-time
Common stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$42.11M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$670.91M	USD	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	1.00B	shares	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	1.00B	shares	Point-in-time
Total current assets	`AssetsCurrent`	$544.55M	USD	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	187.28M	shares	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$39.61M	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$37.17M	USD	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	188.48M	shares	Point-in-time
Right of use asset, net	`OperatingLeaseRightOfUseAsset`	$5.08M	USD	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	187.28M	shares	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	188.48M	shares	Point-in-time
Right of use asset, net	`OperatingLeaseRightOfUseAsset`	$5.83M	USD	Point-in-time
Goodwill and intangible assets, net	`IntangibleAssetsNetIncludingGoodwill`	$40.29M	USD	Point-in-time
Goodwill and intangible assets, net	`IntangibleAssetsNetIncludingGoodwill`	$40.19M	USD	Point-in-time
Other assets	`OtherAssetsNoncurrent`	$6.04M	USD	Point-in-time
Other assets	`OtherAssetsNoncurrent`	$5.96M	USD	Point-in-time
Total assets	`Assets`	$761.75M	USD	Point-in-time
Total assets	`Assets`	$633.86M	USD	Point-in-time
Medical expenses payable	`MedicalExpensesPayableCurrent`	$170.13M	USD	Point-in-time
Medical expenses payable	`MedicalExpensesPayableCurrent`	$185.67M	USD	Point-in-time
Accounts payable and accrued expenses	`AccountsPayableAndAccruedLiabilitiesCurrent`	$31.98M	USD	Point-in-time
Accounts payable and accrued expenses	`AccountsPayableAndAccruedLiabilitiesCurrent`	$22.86M	USD	Point-in-time
Deferred premium revenue	`ContractWithCustomerLiabilityCurrent`	$308.00K	USD	Point-in-time
Deferred premium revenue	`ContractWithCustomerLiabilityCurrent`	$141.08M	USD	Point-in-time
Accrued compensation	`AccruedCompensation`	$27.54M	USD	Point-in-time
Accrued compensation	`AccruedCompensation`	$24.57M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$229.96M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$374.19M	USD	Point-in-time
Long-term debt, net of debt issuance costs	`LongTermDebtNoncurrent`	$160.90M	USD	Point-in-time
Long-term debt, net of debt issuance costs	`LongTermDebtNoncurrent`	$161.12M	USD	Point-in-time
Long-term portion of lease liabilities	`OperatingLeaseLiabilityNoncurrent`	$2.50M	USD	Point-in-time
Long-term portion of lease liabilities	`OperatingLeaseLiabilityNoncurrent`	$3.70M	USD	Point-in-time
Total liabilities	`Liabilities`	$394.56M	USD	Point-in-time
Total liabilities	`Liabilities`	$537.81M	USD	Point-in-time
Commitments and Contingencies (Note 12)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Commitments and Contingencies (Note 12)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Preferred stock, $.001 par value; 100,000,000 and 100,000,000 shares authorized as of March 31, 2023 and December 31, 2022, respectively; no shares issued and outstanding as of March 31, 2023 and December 31, 2022	`PreferredStockValue`	-	USD	Point-in-time
Preferred stock, $.001 par value; 100,000,000 and 100,000,000 shares authorized as of March 31, 2023 and December 31, 2022, respectively; no shares issued and outstanding as of March 31, 2023 and December 31, 2022	`PreferredStockValue`	-	USD	Point-in-time
Common stock, $.001 par value; 1,000,000,000 shares authorized as of March 31, 2023 and December 31, 2022; 188,362,035 and 187,280,015 shares issued and outstanding as of March 31, 2023 and December 31, 2022, respectively	`CommonStockValue`	$188.00K	USD	Point-in-time
Common stock, $.001 par value; 1,000,000,000 shares authorized as of March 31, 2023 and December 31, 2022; 188,362,035 and 187,280,015 shares issued and outstanding as of March 31, 2023 and December 31, 2022, respectively	`CommonStockValue`	$187.00K	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$970.18M	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$992.16M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-732.24M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-769.52M	USD	Point-in-time
Total Alignment Healthcare, Inc. stockholders' equity	`StockholdersEquity`	$222.82M	USD	Point-in-time
Total Alignment Healthcare, Inc. stockholders' equity	`StockholdersEquity`	$238.13M	USD	Point-in-time
Noncontrolling interest	`MinorityInterest`	$1.12M	USD	Point-in-time
Noncontrolling interest	`MinorityInterest`	$1.18M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$306.06M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$239.30M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$293.29M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$223.94M	USD	Point-in-time
Total liabilities and stockholders' equity	`LiabilitiesAndStockholdersEquity`	$633.86M	USD	Point-in-time
Total liabilities and stockholders' equity	`LiabilitiesAndStockholdersEquity`	$761.75M	USD	Point-in-time

Income Statement 38 line items

Line Item	Tag	Value	Unit	Period
Earned premiums	`PremiumsEarnedNet`	$434.81M	USD	1 Quarter
Earned premiums	`PremiumsEarnedNet`	$345.29M	USD	1 Quarter
Other	`RevenueNotFromContractWithCustomer`	$234.00K	USD	1 Quarter
Other	`RevenueNotFromContractWithCustomer`	$4.34M	USD	1 Quarter
Total revenues	`Revenues`	$345.53M	USD	1 Quarter
Total revenues	`Revenues`	$439.15M	USD	1 Quarter
Medical expenses	`MedicalExpenses`	$303.76M	USD	1 Quarter
Medical expenses	`MedicalExpenses`	$396.31M	USD	1 Quarter
Selling, general, and administrative expenses	`SellingGeneralAndAdministrativeExpense`	$74.29M	USD	1 Quarter
Selling, general, and administrative expenses	`SellingGeneralAndAdministrativeExpense`	$70.41M	USD	1 Quarter
Depreciation and amortization	`DepreciationDepletionAndAmortization`	$3.95M	USD	1 Quarter
Depreciation and amortization	`DepreciationDepletionAndAmortization`	$4.92M	USD	1 Quarter
Total expenses	`OperatingExpenses`	$382.00M	USD	1 Quarter
Total expenses	`OperatingExpenses`	$471.64M	USD	1 Quarter
Loss from operations	`OperatingIncomeLoss`	$-32.49M	USD	1 Quarter
Loss from operations	`OperatingIncomeLoss`	$-36.48M	USD	1 Quarter
Interest expense	`InterestExpense`	$4.40M	USD	1 Quarter
Interest expense	`InterestExpense`	$5.02M	USD	1 Quarter
Other income	`OtherNonOperatingExpenseIncome`	$-59.00K	USD	1 Quarter
Other income	`OtherNonOperatingExpenseIncome`	$-138.00K	USD	1 Quarter
Total other expenses	`OtherNonoperatingIncomeExpense`	$-4.34M	USD	1 Quarter
Total other expenses	`OtherNonoperatingIncomeExpense`	$-4.88M	USD	1 Quarter
Loss before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-40.82M	USD	1 Quarter
Loss before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-37.37M	USD	1 Quarter
Provision for income taxes	`IncomeTaxExpenseBenefit`	-	USD	1 Quarter
Provision for income taxes	`IncomeTaxExpenseBenefit`	$1.00K	USD	1 Quarter
Net loss	`ProfitLoss`	$-40.82M	USD	1 Quarter
Net loss	`ProfitLoss`	$-37.37M	USD	1 Quarter
Less: Net loss attributable to noncontrolling interest	`NetIncomeLossAttributableToNoncontrollingInterest`	-	USD	1 Quarter
Less: Net loss attributable to noncontrolling interest	`NetIncomeLossAttributableToNoncontrollingInterest`	$-87.00K	USD	1 Quarter
Net loss attributable to Alignment Healthcare, Inc.	`NetIncomeLoss`	$-40.82M	USD	1 Quarter
Net loss attributable to Alignment Healthcare, Inc.	`NetIncomeLoss`	$-37.28M	USD	1 Quarter
Total weighted-average common shares outstanding - basic and diluted	`WeightedAverageNumberOfSharesOutstandingNetOfRestrictedSharesOfCommonStockBasicAndDiluted`	183.11M	shares	1 Quarter
Total weighted-average common shares outstanding - basic and diluted	`WeightedAverageNumberOfSharesOutstandingNetOfRestrictedSharesOfCommonStockBasicAndDiluted`	178.87M	shares	1 Quarter
Net loss per share - basic	`EarningsPerShareBasic`	$-0.23	USD	1 Quarter
Net loss per share - basic	`EarningsPerShareBasic`	$-0.20	USD	1 Quarter
Net loss per share - diluted	`EarningsPerShareDiluted`	$-0.23	USD	1 Quarter
Net loss per share - diluted	`EarningsPerShareDiluted`	$-0.20	USD	1 Quarter

Cash Flow Statement 73 line items

Line Item	Tag	Value	Unit	Period
Net loss	`ProfitLoss`	$-40.82M	USD	1 Quarter
Net loss	`ProfitLoss`	$-37.37M	USD	1 Quarter
Provision for credit loss	`ProvisionForDoubtfulAccounts`	$1.00K	USD	1 Quarter
Provision for credit loss	`ProvisionForDoubtfulAccounts`	$53.00K	USD	1 Quarter
Depreciation and amortization	`DepreciationAndAmortization`	$4.98M	USD	1 Quarter
Depreciation and amortization	`DepreciationAndAmortization`	$3.99M	USD	1 Quarter
Amortization-investment discount	`InvestmentIncomeAmortizationOfDiscount`	$351.00K	USD	1 Quarter
Amortization-investment discount	`InvestmentIncomeAmortizationOfDiscount`	-	USD	1 Quarter
Amortization-debt issuance costs	`AmortizationOfFinancingCosts`	$566.00K	USD	1 Quarter
Amortization-debt issuance costs	`AmortizationOfFinancingCosts`	$305.00K	USD	1 Quarter
Amortization of payment-in-kind interest	`PaidInKindInterest`	$1.07M	USD	1 Quarter
Amortization of payment-in-kind interest	`PaidInKindInterest`	-	USD	1 Quarter
Equity-based compensation	`ShareBasedCompensation`	$21.98M	USD	1 Quarter
Equity-based compensation	`ShareBasedCompensation`	$28.05M	USD	1 Quarter
Non-cash lease expense	`OperatingLeaseCost`	$717.00K	USD	1 Quarter
Non-cash lease expense	`OperatingLeaseCost`	$715.00K	USD	1 Quarter
Accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$32.39M	USD	1 Quarter
Accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$26.05M	USD	1 Quarter
Prepaid expenses and other current assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$5.08M	USD	1 Quarter
Prepaid expenses and other current assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$15.79M	USD	1 Quarter
Other assets	`IncreaseDecreaseInOtherOperatingAssets`	$-4.00K	USD	1 Quarter
Other assets	`IncreaseDecreaseInOtherOperatingAssets`	$167.00K	USD	1 Quarter
Medical expenses payable	`IncreaseDecreaseInMedicalExpensesPayable`	$29.08M	USD	1 Quarter
Medical expenses payable	`IncreaseDecreaseInMedicalExpensesPayable`	$15.54M	USD	1 Quarter
Accounts payable and accrued expenses	`IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities`	$-1.62M	USD	1 Quarter
Accounts payable and accrued expenses	`IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities`	$-9.21M	USD	1 Quarter
Deferred premium revenue	`IncreaseDecreaseInContractWithCustomerLiability`	$-37.00K	USD	1 Quarter
Deferred premium revenue	`IncreaseDecreaseInContractWithCustomerLiability`	$140.77M	USD	1 Quarter
Accrued compensation	`IncreaseDecreaseInAccruedCompensation`	$-2.97M	USD	1 Quarter
Accrued compensation	`IncreaseDecreaseInAccruedCompensation`	$-364.00K	USD	1 Quarter
Lease liabilities	`IncreaseDecreaseInOperatingLeaseLiability`	$-1.11M	USD	1 Quarter
Lease liabilities	`IncreaseDecreaseInOperatingLeaseLiability`	$-1.03M	USD	1 Quarter
Net cash provided by (used in) operating activities	`NetCashProvidedByUsedInOperatingActivities`	$85.11M	USD	1 Quarter
Net cash provided by (used in) operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-11.64M	USD	1 Quarter
Purchase of business, net of cash received	`PaymentsToAcquireAssetsInvestingActivities`	-	USD	1 Quarter
Purchase of business, net of cash received	`PaymentsToAcquireAssetsInvestingActivities`	$1.11M	USD	1 Quarter
Purchase of investments	`PaymentsToAcquireInvestments`	$104.24M	USD	1 Quarter
Purchase of investments	`PaymentsToAcquireInvestments`	$850.00K	USD	1 Quarter
Sale of investments	`ProceedsFromSaleOfLongtermInvestments`	$1.10M	USD	1 Quarter
Sale of investments	`ProceedsFromSaleOfLongtermInvestments`	$750.00K	USD	1 Quarter
Acquisition of property and equipment	`ProceedsFromAcquisitionOfPropertyAndEquipment`	$-4.91M	USD	1 Quarter
Acquisition of property and equipment	`ProceedsFromAcquisitionOfPropertyAndEquipment`	$-7.29M	USD	1 Quarter
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-110.43M	USD	1 Quarter
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-6.13M	USD	1 Quarter
Contributions from noncontrolling interest holders	`ProceedsFromMinorityShareholders`	-	USD	1 Quarter
Contributions from noncontrolling interest holders	`ProceedsFromMinorityShareholders`	$30.00K	USD	1 Quarter
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$30.00K	USD	1 Quarter
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	-	USD	1 Quarter
Net decrease in cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect`	$-25.29M	USD	1 Quarter
Net decrease in cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect`	$-17.77M	USD	1 Quarter
Cash, cash equivalents and restricted cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$468.35M	USD	Point-in-time
Cash, cash equivalents and restricted cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$411.30M	USD	Point-in-time
Cash, cash equivalents and restricted cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$386.01M	USD	Point-in-time
Cash, cash equivalents and restricted cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$450.58M	USD	Point-in-time
Cash, cash equivalents and restricted cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$468.35M	USD	Point-in-time
Cash, cash equivalents and restricted cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$411.30M	USD	Point-in-time
Cash, cash equivalents and restricted cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$386.01M	USD	Point-in-time
Cash, cash equivalents and restricted cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$450.58M	USD	Point-in-time
Cash paid for interest	`InterestPaidNet`	$4.28M	USD	1 Quarter
Cash paid for interest	`InterestPaidNet`	$2.76M	USD	1 Quarter
Acquisition of property in accounts payable	`AcquisitionOfPropertyInAccountsPayable`	$331.00K	USD	1 Quarter
Acquisition of property in accounts payable	`AcquisitionOfPropertyInAccountsPayable`	$10.00K	USD	1 Quarter
Purchase of business in accounts payable	`CapitalExpendituresIncurredButNotYetPaid`	$240.00K	USD	1 Quarter
Purchase of business in accounts payable	`CapitalExpendituresIncurredButNotYetPaid`	-	USD	1 Quarter
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$448.83M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$409.55M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$384.26M	USD	Point-in-time
Restricted cash in other assets	`RestrictedCashAndCashEquivalents`	$1.75M	USD	Point-in-time
Restricted cash in other assets	`RestrictedCashAndCashEquivalents`	$1.75M	USD	Point-in-time
Total	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$468.35M	USD	Point-in-time
Total	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$411.30M	USD	Point-in-time
Total	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$386.01M	USD	Point-in-time
Total	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$450.58M	USD	Point-in-time

Stockholders Equity 22 line items

Line Item	Tag	Value	Unit	Period
Beginning Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$306.06M	USD	Point-in-time
Beginning Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$239.30M	USD	Point-in-time
Beginning Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$293.29M	USD	Point-in-time
Beginning Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$223.94M	USD	Point-in-time
Beginning Balance, Shares	`CommonStockSharesIssued`	187.28M	shares	Point-in-time
Beginning Balance, Shares	`CommonStockSharesIssued`	188.48M	shares	Point-in-time
Net loss	`ProfitLoss`	$-40.82M	USD	1 Quarter
Net loss	`ProfitLoss`	$-37.37M	USD	1 Quarter
Net loss attributable to Alignment Healthcare, Inc.	`NetIncomeLoss`	$-40.82M	USD	1 Quarter
Net loss attributable to Alignment Healthcare, Inc.	`NetIncomeLoss`	$-37.28M	USD	1 Quarter
Noncontrolling interest attributable to subsidiary	`NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance`	$30.00K	USD	1 Quarter
Issuance of common stock upon vesting of restricted stock units	`IssuanceOfCommonStockUponVestingOfRestrictedStockUnits`	383,508.00	shares	1 Quarter
Issuance of common stock upon vesting of restricted stock units values	`IssuanceOfCommonStockUponVestingOfRestrictedStockUnitsValues`	$1.00K	USD	1 Quarter
Forfeitures	`StockIssuedDuringPeriodValueShareBasedCompensationForfeited`	-	USD	1 Quarter
Equity-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$21.98M	USD	1 Quarter
Equity-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$28.05M	USD	1 Quarter
Ending Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$306.06M	USD	Point-in-time
Ending Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$239.30M	USD	Point-in-time
Ending Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$293.29M	USD	Point-in-time
Ending Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$223.94M	USD	Point-in-time
Ending Balance, Shares	`CommonStockSharesIssued`	187.28M	shares	Point-in-time
Ending Balance, Shares	`CommonStockSharesIssued`	188.48M	shares	Point-in-time

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.